About
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its proprietary virus-like particle (VLP) technology. Its lead candidate, AU-011, is designed to selectively target ocular cancers, enabling the targeted destruction of tumor cells while protecting surrounding healthy tissue. With a robust clinical pipeline aimed at addressing significant unmet needs in oncology, Aura is backed by an experienced management team and strategic partnerships. The company's commitment to innovation and thorough clinical evaluation positions it for significant impact in the area of targeted cancer therapies, catering to a rapidly evolving market landscape.
Advanced charting, extended hours trading, and free stock for new accounts.
Price data sourced from Polygon.io (previous trading day close). Fundamentals from Alpha Vantage. Insider trades from SEC EDGAR. Cached via Cloudflare KV.